ArticleBlood2022
Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19.
Abstract read
In one paragraph
Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clonal hematopoiesis of indeterminate potential as a prognostic factor: a systematic review and meta-analysis.Blood advances · 2024Pooled it
- Clonal hematopoiesis of indeterminate potential: a multisystem hub bridging hematopoietic dysfunction with non-hematopoietic diseases.Military Medical Research · 2025Review
- A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis.British journal of haematology · 2025Review
- Review
- Cerebromicrovascular mechanisms contributing to long COVID: implications for neurocognitive health.GeroScience · 2025Review
- Omicron variant infection worsen the prognosis of haemodialysis (HD) patients.Annals of medicine · 2024Article
- Invasive Assessment of Coronary Artery Disease in Clonal Hematopoiesis of Indeterminate Potential.Circulation. Genomic and precision medicine · 2024Article
- Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies.Blood advances · 2024Article
- Multiomic profiling of human clonal hematopoiesis reveals genotype and cell-specific inflammatory pathway activation.Blood advances · 2024Article
- Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis.Blood cancer discovery · 2024Article
- Clonal hematopoiesis and COVID-19 hospitalization in Danish adults.HemaSphere · 2024Article
- Clonal haematopoiesis, ageing and kidney disease.Nature reviews. Nephrology · 2024Review
- Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma.Cancer research communications · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Peter G MillerCenter for Cancer Research and Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA.ORCID 0000-0002-6797-9335
Geoffrey G FellDepartment of Data Sciences, Dana Farber Cancer Institute, Boston, MA.ORCID 0000-0001-6436-6691
Brody H FoyDepartment of Pathology & Center for Systems Biology, Massachusetts General Hospital, Boston, MA.
Allison K SchererDivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA.ORCID 0000-0003-3735-3873
Christopher J GibsonDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.
Adam S SperlingCancer Program, Broad Institute of Harvard and MIT, Cambridge, MA.ORCID 0000-0002-9369-4413
Bala B BurugulaDepartment of Human Genetics, University of Michigan, Ann Arbor, MI.ORCID 0000-0003-1114-6964
Tetsushi NakaoCancer Program, Broad Institute of Harvard and MIT, Cambridge, MA.ORCID 0000-0001-9979-2682
Md M UddinCancer Program, Broad Institute of Harvard and MIT, Cambridge, MA.ORCID 0000-0003-1846-0411
Hailey WarrenDivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA.
Lynn BryDepartment of Pathology, Brigham and Women's Hospital, Boston, MA.
Olga PozdnyakovaDepartment of Pathology, Brigham and Women's Hospital, Boston, MA.ORCID 0000-0001-8376-0344
Matthew J FrigaultCenter for Cancer Research and Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA.
Alex G BickDivision of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Donna NeubergDepartment of Data Sciences, Dana Farber Cancer Institute, Boston, MA.
John M HigginsDepartment of Pathology & Center for Systems Biology, Massachusetts General Hospital, Boston, MA.
Michael K MansourDivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA.ORCID 0000-0001-8892-8695
Pradeep NatarajanCancer Program, Broad Institute of Harvard and MIT, Cambridge, MA.ORCID 0000-0001-8402-7435
Annette S KimDepartment of Pathology, Brigham and Women's Hospital, Boston, MA.ORCID 0000-0002-8699-2439
Jacob O KitzmanDepartment of Human Genetics, University of Michigan, Ann Arbor, MI.ORCID 0000-0002-6145-882X
Benjamin L EbertCancer Program, Broad Institute of Harvard and MIT, Cambridge, MA.ORCID 0000-0003-0197-5451
Funding
TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI Zuzana Tothova · 1996 to 2026
$52.5MSTRUCTURE-FUNCTION RELATIONSHIPS IN THE ALIMENTARY TRACTP30DK034854 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WAYNE I LENCER · 1986 to 2026
$32.4MTargeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI ASTER, JON C. · 2017 to 2021
$10.6MFunctional Genomic Dissection of Refractory AnemiaR01HL082945 · NHLBI · DANA-FARBER CANCER INSTITUTE · PI EBERT, BENJAMIN LEVINE · 2005 to 2022
$6.8MClonal hematopoiesis in the Womens Health Initiative Memory StudyR01HL148565 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ALEXANDER P REINER, Eric A. Whitsel · 2019 to 2026
$5.9MClonal hematopoiesis in humans: determinants of development and progressionR01HL148050 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI BALLANTYNE, CHRISTIE MITCHELL, NATARAJAN, PRADEEP · 2019 to 2022
$5.9MThe role of clonal hematopoiesis in the development and therapy of myeloid malignanciesR35CA253125 · NCI · DANA-FARBER CANCER INST · PI EBERT, BENJAMIN LEVINE · 2020 to 2024
$4.9MCLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL IN CHRONIC KIDNEY DISEASE PATIENTSR01DK125782 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KELLY, TANIKA NICOLE · 2021 to 2025
$3.3MClonal hematopoiesis of indeterminate potential and HIV in the REPRIEVE trialR01HL151283 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI NATARAJAN, PRADEEP · 2020 to 2023
$2.5MThe role of spleen tyrosine kinase (syk) in neutrophil responses to pathogenic fungi.R01AI132638 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MANSOUR, MICHAEL K · 2018 to 2021
$1.6MDefining mechanisms of thalidomide analog resistanceK08CA252174 · NCI · DANA-FARBER CANCER INST · PI SPERLING, ADAM · 2020 to 2024
$1.3MRole of PPM1D and PPM1D mutations in hematopoiesis and response to stressK08CA263183 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, PETER GRANT · 2021 to 2025
$1.1MNCI NIH HHS K08 CA252174NCI NIH HHS K08 CA263183NCI NIH HHS P01 CA066996NCI NIH HHS P50 CA206963NCI NIH HHS R35 CA253125NHLBI NIH HHS R01 HL082945NHLBI NIH HHS R01 HL148050NHLBI NIH HHS R01 HL148565NHLBI NIH HHS R01 HL151283NIAID NIH HHS R01 AI132638NIDDK NIH HHS P30 DK034854NIDDK NIH HHS R01 DK125782Wellcome Trust
Abstract
PubMed holds no abstract for this paper.
Indexed as
Clonal HematopoiesisCOVID-19Clonal EvolutionHematopoiesisHumansMutation
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.